The company that developed a bracelet for treating atrial fibrillation and raises $30 million

Israeli company StimCardio has raised $30 million to develop a non-invasive bracelet for treating atrial fibrillation. In trials, the device reduced symptoms by about 80% and recurrence of fibrillation by 50%.

Israeli company StimCardio has raised $30 million to develop a non-invasive bracelet that treats atrial fibrillation through nerve stimulation. The funding round was led by Metis Medtech fund, with participation from Catalyst Health Ventures and several medical device companies. In a first trial, the device reduced symptoms by about 80% among patients who had not undergone ablation, and in a second trial it reduced recurrence of fibrillation after ablation by 50%. The company plans a pivotal trial followed by FDA submission. Additionally, TIME magazine selected an original Israeli invention, Dekoda by Kohler Health, for its list of the best inventions of 2026. Almeda will record a profit of about $5 million from the sale of Taylormed, its second exit this year. Ichilov and Wonderful are collaborating in the field of medical artificial intelligence.